

INDEX

A

- Acute respiratory failure
 - associated with tuberculosis, 91-93, 103
 - associated with viral infections, 57-62
- African trypanosomiasis, 145-162
 - central nervous system (CNS) disease, 148
 - clinical presentation of, 149-150
 - diagnosis of, 150-151
 - diminazene, for treatment of, 153, 158
 - elfornitine, for treatment of, 156, 158
 - epidemiology of, 146
 - future therapies for, 157
 - immunology of, 148
 - melarsoprol, for treatment of, 154-156, 158
 - morphology of, 146
 - nifurtimox, for treatment of, 156-158
 - pathogenesis of, 147-148
 - pentamidine, for treatment of, 153, 158
 - suramin, for treatment of, 152-153, 158
 - treatment of, 152-159
 - vector of, 147
 - vector control and social programs for, 159
- Amoebiasis, 167-171
 - amoebic liver abscess, 168
 - acute amoebic colitis, 168
 - complications of amoebic colitis, 168
 - detection of amoebae, 170
 - diagnosis of, 169-170
 - extraintestinal amoebiasis, 168
 - geographical distribution of, 167
 - non-specific laboratory findings in, 169-170
 - pathogenesis and clinical presentation of, 167
 - serological tests for, 170
 - transmission cycle of, 167
 - treatment of, 170-171
- Artemesinins, for treatment of malaria, 6-7, 23
- Aspergillosis, 186-187

B

- Blastomycosis, 204-211
 - clinical manifestations of, 206-208
 - diagnosis of, 208-210
 - epidemiology of, 204-205
 - pathogenesis of, 205-206
 - treatment of, 210-211

C

- Candidiasis, 184-186
 - clinical features of, 185-186
 - treatment of systemic candidiasis, 186
- Coccidioidomycosis, 189, 211-221
 - clinical manifestations of, 213-216
 - diagnosis of, 216-218
 - epidemiology of, 211-212
 - pathogenesis of, 212-213
 - treatment of, 218-221
- Cryptococcal infection, 182-184
 - central nervous system infection, 182-183
 - clinical presentation of, 182-183
 - other organs, 183
 - pulmonary cryptococcosis, 183
 - treatment of, 183-184
- Cytomegalovirus (CMV), 46-47, 67, 68, 73

F

- Fungal infections, 181-193, 195-226
 - aspergillosis, 186-187
 - blastomycosis, 204-211
 - candidiasis, 184-186
 - cryptococcal infection, 182-184
 - coccidioidomycosis, 189, 211-221
 - histoplasmosis, 187-189, 196-204
 - Penicillium marneffei*, 190

H

- Hantavirus, 61
- Hemorrhagic fever viruses, 39-41, 63-65, 70-71
- Hepatitis, 44-45, 68
- Herpes simplex virus type 1 encephalitis, 46, 59, 65-67
- Histoplasmosis, 187-189, 196-204
 - acute pneumonitis due to, 187-188
 - chronic pulmonary histoplasmosis, 188
 - clinical manifestations of, 198
 - diagnosis of, 200-203
 - disseminated histoplasmosis, 188-189
 - epidemiology of, 196-197
 - histoplasmosis and AIDS, 189
 - histoplasmosis and the ICU, 189
 - pathogenesis of, 197-198
 - progressive disseminated histoplasmosis, 198-200
 - the pathogen, 196-197
 - treatment of, 203-204
- Human immunodeficiency virus (HIV), 117-125, 127-144
 - advance directives in, 122
 - AIDS-associated malignancies, 132
 - burns and, 120
 - central nervous system infections in association with, 136-137
 - CD4 T-lymphocytes in, 121-122

Guillain-Barre syndrome and, 120
gynaecological conditions and, 120
HIV-associated drug toxicities in, 131-132
HIV-associated organ damage, 131
highly active antiretroviral therapy (HAART) for, 120-121
implications for critical care, 117-118
mycobacterial infections, in association with, 134-135
occupational exposure to HIV infection, 122-123
opportunistic infections in the ICU, in association with, 132-137
outcome in, 119
other pneumonias, in association with, 135-136
Pneumocystis pneumonia in, 133-134, 139
predictors of ICU outcomes in HIV-infected patients, 137-138, 140
reasons for ICU admission in HIV-infected patients, 129-137
surgical patients and, 119-120

I

Influenza virus, 41-42, 57, 58, 59, 60, 62, 72, 73

M

Malaria, 1-16, 17-37
acidosis in, 10
adjunctive therapy for, 26
anaemia in, 7-8, 32
artemesinins for, 6-7, 23
bleeding disorders in, 32
cerebral malaria, 8, 30
clinical manifestations of, 2-3, 20
complications of malaria and their management, 7-13
diagnosis of, 3-4, 21-22
definition of severe malaria, 18
disseminated intravascular coagulation (DIC) in, 9-10
epidemiology of malaria in US travelers, 18
exchange transfusion for, 12-13, 26-27
fever in, 31-32
fluid, electrolyte and acid base disturbances in, 28-29
haemaglobinuria and Blackwater fever in, 10, 32-33
hepatic dysfunction in, 9-10
HIV and severe malaria, 12
hypoglycaemia in, 11, 31
hypotension/shock in, 29
indicators of severe malaria, 3
laboratory diagnosis of, 3-4
management of severe malaria and its complications, 27-33
non-falciparum malaria, 11
other drugs for, 7, 25
pathogenesis of severe malaria, 2, 18-19
predictors of mortality in, 13
pregnancy and, 11
prognosis of, 33
pulmonary edema in, 9, 29-30
quinidine gluconate for, 6, 23-25

- quinine for, 5-6, 22-25
- renal failure in, 8-9, 30
- respiratory failure in, 9
- secondary infection in, 10
- seizures in, 30-31
- shock in, 11
- treatment of severe malaria, 4-7, 22-26

Measles, 45-46

Meningitis

- associated with tuberculosis, 94-95, 106
- viral meningitis and encephalitis, 65

P

Parasitic infections, 163-179

- amoebiasis, 167-171
- pulmonary eosinophilic syndromes, 175-176
- schistosomiasis, 171-175
- strongyloidiasis, 163-166

Penicillium marneffei, 190

Pericarditis

- associated with tuberculosis, 93-94, 106

Pulmonary eosinophilic syndromes, 175-176

- tropical eosinophilia, 175-176
- loffler's syndrome, 175-176

Q

Quinidine, for treatment of malaria, 6, 23-25

Quinine, for treatment of malaria, 5-6, 23-25

R

Respiratory syncytial virus, 42-43, 57, 58, 59, 60

S

Schistosomiasis, 171-175

- clinical features of, 172-173
- diagnosis of, 173-174
- geographic distribution of, 171
- life cycle of, 172
- parasitological diagnosis of, 173
- radiological diagnosis of, 174
- serological diagnosis of, 174
- stage of invasion of, 172
- stage of maturation of, 172-173
- treatment of, 174-175

Severe acute respiratory syndrome (SARS), 47-52, 60

- clinical definition of, 49
- clinical features of, 49
- diagnosis of, 48
- infection control for, 51
- mortality of, 50
- organism causing, 48

- treatment of, 49-50
- Smallpox, 69-70
- Strongyloidiasis, 163-166
 - clinical features of severe, complicated infection, 165
 - diagnosis of, 165-166
 - geographic distribution of, 163
 - life cycle of, 163-164
 - pathogenesis and clinical presentation of, 164
 - severe, complicated strongyloidiasis, 164-165
 - treatment of, 166

- T**
- Trypanosomiasis, 145-162
 - see also* African trypanosomiasis
- Tuberculosis, 89-99, 101-116
 - advances in diagnosis of, 107-108
 - acute respiratory failure in, 91-93, 103
 - adrenocortical insufficiency in, 95, 104
 - controlling TB transmission in the ICU, 109-110
 - critical illness in association with tuberculosis, 91-96, 102
 - drug toxicity in, 95-96
 - epidemiology of, 101-102
 - forms of tuberculosis pertinent to the intensivist, 102-103
 - future of tuberculosis treatment and prevention, 96, 111-112
 - massive hemoptysis due to, 104-105
 - meningitis in, 94-95
 - other presentations of, 105-106
 - pericarditis in, 93-94
 - resurgence of tuberculosis, 90-91
 - respiratory failure in, 91-93, 103
 - septic shock in, 103-104
 - treatment and management advice for, 108-109

- V**
- Varicella virus, 43,44
- Viral infections, 39-56, 57-87
 - acute respiratory distress syndrome (ARDS) due to, 61
 - acute respiratory failure due to, 57-62
 - bioterrorism agents, 69-71
 - cytomegalovirus (CMV), 46-47
 - dengue fever, 62-63
 - fulminant hepatitis due to, 68
 - Guillain-Barre syndrome, 61-62
 - Hantaviruses, 61
 - hepatitis, 44-45, 68
 - hepatitis viruses, 68
 - Herpes simplex virus type 1 encephalitis, 46
 - Herpes viruses, 67, 73
 - influenza, 41-42
 - measles, 45-46
 - pancreatitis due to, 68
 - respiratory syncytial virus, 42-43

rhabdomyolysis due to, 68
severe acute respiratory syndrome (SARS), 47-51, 60
shock due to, 62-65
smallpox, 69-70
special or immunosuppressed hosts and, 71-74
varicella pneumonia, 43-44
viral hemorrhagic fevers, 39-41, 63-65, 70-71
viral meningitis and encephalitis, 46, 65-67
West Nile virus, 65, 66

W

West Nile virus, 65, 66